98%
921
2 minutes
20
Although the use of donation after cardiac death (DCD) donor organs has been shown to be a viable option for liver and kidney transplant recipients, outcomes after simultaneous liver and kidney (SLK) transplantation using DCD donors are less clear. We performed a retrospective analysis of 37 adult, primary SLK transplants performed at our center between January 1, 1998 and December 31, 2008. Thirty-two patients received donation after brain death (DBD) organs, and 5 patients received DCD organs. SLK recipients in the 2 groups were similar with respect to age, gender, race, body mass index, donor race, and donor body mass index. The calculated Model for End-Stage Liver Disease scores and pretransplant glomerular filtration rates were similar between the groups. DCD donors were younger and had shorter liver cold ischemia times. The median DCD donor warm ischemia time was 19.0 minutes (6.0-25.0 minutes). The recipient surgical times and hospital lengths of stay were comparable between the groups. Delayed graft function was more frequent in DCD renal allografts (80% versus 31%, P = 0.06). The 1-year graft survival rates for liver allografts (100% for the DCD group versus 94% for the DBD group) and kidney allografts (100% for the DCD group versus 94% for the DBD group) were similar. In conclusion, patients undergoing DCD SLK transplantation have comparable 1-year patient and graft survival rates and acceptable perioperative morbidity in comparison with DBD SLK transplant recipients. Although long-term outcomes remain unknown, the utilization of DCD organs for SLK transplantation should be considered a valid approach to safely expanding the donor organ pool.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088423 | PMC |
http://dx.doi.org/10.1002/lt.22264 | DOI Listing |
Kidney Blood Press Res
August 2025
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder caused by a deficiency of the hepatic peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT), which catalyses the conversion of glyoxylate to glycine, resulting in increased oxalate production. The clinical consequences of the progressive build up of oxalates include nephrocalcinosis, nephrolithiasis, chronic kidney disease and ultimately renal failure with extra-renal involvement. The diagnosis of PH1 is challenging due to the non-specific nature of its symptoms and the need for costly genetic testing.
View Article and Find Full Text PDFEndocrinol Diabetes Metab
September 2025
Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Liver transplantation is associated with various metabolic disorders. Peri-transplant hyperglycemia is among the most frequent metabolic disorders among liver transplant recipients. Hyperglycemia following liver transplantation can increase the risk of post-transplant complications, potentially impacting both graft and recipient outcomes.
View Article and Find Full Text PDFNat Metab
September 2025
Department of Bioinformatics and Biochemistry, Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Itaconate is an immunomodulatory metabolite that alters mitochondrial metabolism and immune cell function. This organic acid is endogenously synthesized by tricarboxylic acid (TCA) metabolism downstream of TLR signalling. Itaconate-based treatment strategies are under investigation to mitigate numerous inflammatory conditions.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.
This study aimed to develop a predictive model and construct a graded nomogram to estimate the risk of severe acute kidney injury (AKI) in patients without preexisting kidney dysfunction undergoing liver transplantation (LT). Patients undergoing LT between January 2022 and June 2023 were prospectively screened. Severe AKI was defined as Kidney Disease: Improving Global Outcomes stage 3.
View Article and Find Full Text PDFHeart Lung Circ
September 2025
Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA, Australia; Medical School, The University of Western Australia, Perth, WA, Australia; Curtin Medical School, Curtin University, Bentley, WA, Australia. Electronic address:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, with a reach extending beyond the liver to include other metabolic syndrome-related disorders. Cardiovascular disease and type 2 diabetes mellitus are recognised non-communicable disorders and often downstream complications of MASLD and share similar risk factors. However, MASLD has not been afforded parity alongside other cardiometabolic non-communicable disorders, including the cardiovascular-kidney-metabolic (CKM) syndrome.
View Article and Find Full Text PDF